Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Monopar Therapeutics | Chief Scientific Officer, Director | Common Stock | 167K | $56.7K | $0.34 | Mar 31, 2022 | Indirect |
Monopar Therapeutics | Chief Scientific Officer, Director | Restricted Stock Units | 88.8K | $30.2K | $0.34 | Mar 31, 2022 | Direct |
Monopar Therapeutics | Chief Scientific Officer, Director | Common Stock | 22.1K | $7.53K | $0.34 | Mar 31, 2022 | Direct |
ACTUATE THERAPEUTICS, INC. | Chief Operating Officer | Common Stock | 127K | Aug 12, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ACTU | ACTUATE THERAPEUTICS, INC. | Aug 12, 2024 | 0 | $0 | 3 | Aug 12, 2024 | Chief Operating Officer |
MNPR | Monopar Therapeutics | Mar 31, 2022 | 3 | -$1.2K | 4 | Apr 1, 2022 | Chief Scientific Officer, Director |
MNPR | Monopar Therapeutics | Feb 2, 2022 | 2 | $0 | 4 | Feb 4, 2022 | Chief Scientific Officer, Director |
MNPR | Monopar Therapeutics | Jan 1, 2022 | 3 | -$2.15K | 4 | Jan 4, 2022 | Chief Scientific Officer, Director |
MNPR | Monopar Therapeutics | Dec 31, 2021 | 3 | -$1.78K | 4 | Jan 4, 2022 | Chief Scientific Officer, Director |
MNPR | Monopar Therapeutics | Sep 30, 2021 | 3 | -$2.29K | 4 | Oct 1, 2021 | Chief Scientific Officer, Director |
MNPR | Monopar Therapeutics | Jun 30, 2021 | 3 | -$5.55K | 4 | Jul 2, 2021 | Chief Scientific Officer, Director |